Cypress Wealth Services LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 1.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,061 shares of the biopharmaceutical company’s stock after buying an additional 612 shares during the period. Cypress Wealth Services LLC’s holdings in Pfizer were worth $1,256,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Integrated Wealth Concepts LLC boosted its stake in Pfizer by 14.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock worth $2,840,000 after buying an additional 8,445 shares during the last quarter. Halsey Associates Inc. CT boosted its position in Pfizer by 73.8% during the 3rd quarter. Halsey Associates Inc. CT now owns 44,316 shares of the biopharmaceutical company’s stock worth $1,592,000 after acquiring an additional 18,822 shares during the period. Whitnell & Co. boosted its position in Pfizer by 390.0% during the 3rd quarter. Whitnell & Co. now owns 50,507 shares of the biopharmaceutical company’s stock worth $1,815,000 after acquiring an additional 40,200 shares during the period. IHT Wealth Management LLC boosted its position in Pfizer by 20.5% during the 3rd quarter. IHT Wealth Management LLC now owns 72,126 shares of the biopharmaceutical company’s stock worth $2,595,000 after acquiring an additional 12,291 shares during the period. Finally, Altavista Wealth Management Inc. lifted its holdings in shares of Pfizer by 7.3% in the third quarter. Altavista Wealth Management Inc. now owns 116,631 shares of the biopharmaceutical company’s stock valued at $4,191,000 after buying an additional 7,963 shares during the period. 70.21% of the stock is currently owned by institutional investors.

PFE stock traded down $0.03 during midday trading on Tuesday, reaching $39.38. 982,395 shares of the company’s stock traded hands, compared to its average volume of 17,003,996. The company has a market cap of $218.54 billion, a price-to-earnings ratio of 13.13, a PEG ratio of 4.18 and a beta of 0.65. The company has a quick ratio of 0.68, a current ratio of 0.90 and a debt-to-equity ratio of 0.55. The company has a 50-day simple moving average of $38.82 and a two-hundred day simple moving average of $38.21. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $44.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The business had revenue of $12.68 billion for the quarter, compared to analyst estimates of $12.37 billion. During the same period last year, the company earned $0.78 EPS. The firm’s revenue was down 4.6% on a year-over-year basis. Equities research analysts forecast that Pfizer Inc. will post 2.97 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 31st will be paid a $0.38 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, January 30th. This represents a $1.52 annualized dividend and a yield of 3.86%. Pfizer’s dividend payout ratio (DPR) is 48.00%.

PFE has been the topic of a number of recent analyst reports. Credit Suisse Group reaffirmed a “hold” rating and set a $41.30 target price on shares of Pfizer in a research report on Wednesday, November 6th. ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. Bank of America started coverage on Pfizer in a research note on Wednesday, October 16th. They set a “neutral” rating and a $37.00 target price for the company. Royal Bank of Canada started coverage on Pfizer in a research report on Monday, January 6th. They issued an “outperform” rating and a $46.00 price objective for the company. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a research report on Tuesday, October 1st. Nine investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $43.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: What is Cost of Goods Sold (COGS)?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.